HLS Therapeutics Reports Mixed Q2 Results, Reiterates FY25 Outlook

HLS Therapeutics reported mixed Q2 results, with GAAP EPS beating estimates but revenue missing by $5.97M, down 2.4% YoY. Adjusted EBITDA was $5.2M, and cash from operations was $4.6M. The company reaffirmed its FY25 outlook.

HLS Therapeutics Inc. (TSX: HLS) reported mixed financial results for the second quarter and year-to-date of 2025, with GAAP EPS beating estimates but revenue falling short by $5.97 million, down 2.4% year-over-year. The company's adjusted EBITDA was $5.2 million, and cash from operations was $4.6 million. HLS reaffirmed its full-year 2025 outlook despite the mixed performance.

Key highlights of the Q2 2025 results include:
- Revenue decreased by 2% to $14.2 million, missing estimates by $5.97 million.
- Adjusted EBITDA increased by 21% to $5.2 million.
- Cash from operations grew by 83% to $4.6 million.
- The company made principal repayments on its long-term debt totaling $8.5 million.
- HLS expanded its cardiovascular portfolio by licensing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion Therapeutics.

The company's management noted that the year-to-date results reflect continued execution on strategic priorities, with strong underlying performance demonstrated by 29% year-to-date adjusted EBITDA growth, robust cash flow generation, and significant debt repayments.

Looking ahead, HLS is excited about the introduction of NEXLETOL and NEXLIZET in Canada, which have the potential to more than double the size of its cardiovascular business. Health Canada approval is expected by year-end, with a planned launch in Q2 2026.

Reference List:
[1] https://finance.yahoo.com/news/hls-therapeutics-announces-q2-2025-103100196.html